Biocept Joins the Russell Microcap® Index

June 28, 2021 at 08:05 AM EDT

Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will be added to the Russell Microcap Index after the U.S. market opens today, June 28, 2021.

“We are pleased that Biocept will now be included in the Russell Microcap Index, which is a broadly used performance benchmark for smaller growth stocks in the U.S.,” said Michael Nall, President and CEO of Biocept. “This is an exceptionally exciting time with the full commercial launch underway of our novel, proprietary CNSide™ assay that provides physicians with a significantly improved tool to diagnose and manage patients with tumors that have metastasized to the central nervous system. We believe the addition to the Russell Microcap Index will further raise awareness of Biocept within the global investment community.”

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell, a leading global index provider, determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s U.S. indexes. For more information on the Russell Microcap Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About Biocept

Biocept, Inc. develops and performs molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide™ cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept’s patented Target Selector™ technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.

Forward-Looking Statements Disclaimer

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "will," "expect" and "believe" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding our belief that the addition to the Russell Microcap Index will further raise awareness of Biocept within the global investment community, as well as Biocept’s ability to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risks and uncertainties, including: the market prices for our common stock have historically been volatile and will likely continue to be volatile for the foreseeable future; securities or industry analysts could issue an adverse opinion regarding our stock or not publish research or reports about our company, in which case our stock price and trading volume could decline; there is no guarantee that our common stock will continue to be included in the Russell Microcap Index; and our products and services may not perform as expected. These and other risks are described in greater detail under the "Risk Factors" heading of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, as filed with the Securities and Exchange Commission (SEC) on May 12, 2021. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005127/en/

Contacts

Investors

Jody Cain

LHA Investor Relations

Jcain@lhai.com, 310-691-7100

Media

Andrea Sampson

Sampson PR Group

asampson@sampsonprgroup.com, 562-304-0301

About Us

About Cabling Installation & Maintenance

Contact Cabling Installation & Maintenance

Editorial

Advertising and Sponsorship Sales

Subscriptions and Memberships

Feedback/Problems

Biocept Joins the Russell Microcap® Index

Contacts

More News